Sanofi : More ambitious bets so as not to miss a second wave of innovation
>An R&D day to provide details of its roadmap - Yesterday, Sanofi organised its R&D day, the main aim of which was to outline its long-term strategy. The company's track record prompts investors towards caution about the success of the pipeline and the most sceptical amongst them to consider Sanofi as Dupixent-dependent. We do not expect any significant revisions to the figures after the R&D days, but we do expect an increasingly positive sentiment regarding the compa...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.